Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study-Reference-Cited by-同舟云学术

Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study

Published:2019-05-24 Issue:2 Volume:28 Page:691-699
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Aras Elif,Bayraktar-Ekincioglu Aygin^ORCID,Kilickap Saadettin

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-019-04879-x.pdf

Reference19 articles.

1. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for R, Treatment of C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32. https://doi.org/10.1016/j.ejca.2010.10.013

2. Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M (2016) Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract 22(5):702–716. https://doi.org/10.1177/1078155215625459

3. Silvestris N, Del Re M, Azzariti A, Maiello E, Lombardi L, Cinieri S, Guarini A, Brunetti AE, Delcuratolo S, De Vita F, Pisconti S, Danesi R, Colucci G (2012) Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opin Ther Targets 16(Suppl 2):S111–S117. https://doi.org/10.1517/14728222.2011.652089

4. Crawford J, Becker, P. S., Armitage, J.O., Blayney, D. W., Cataland, S.R., Curtin, P., Fynan, T., Griffiths, E. A., Hough, S. et al. (2016) NCCN Guidelines version 2.2016 Myeloid Growth Factors

5. Smith TJ, Bohlke K, Armitage JO (2015) Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 11(6):511–513. https://doi.org/10.1200/JOP.2015.006742

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Acupuncture for Relieving Chemotherapy-Induced Bone Marrow Suppression: A Systematic Review with a Meta-analysis and Trial Sequential Analysis;Journal of Integrative and Complementary Medicine;2023-10-01

2. Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia;BMC Health Services Research;2023-05-23

3. Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement;Supportive Care in Cancer;2022-11-05

4. Management of chemotherapy-induced febrile neutropenia and use of granulocyte colony-stimulating factor in patients with soft tissue or bone sarcoma;Journal of Oncology Pharmacy Practice;2022-10-13

5. Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment;BMJ Supportive & Palliative Care;2021-10-27